Merck & Co Inc (MRK)

66.12
0.67 1.00
NYSE : Health Care
Prev Close 65.46
Open 65.51
Day Low/High 65.38 / 66.37
52 Wk Low/High 55.10 / 66.80
Volume 6.48M
Avg Volume 8.82M
Exchange NYSE
Shares Outstanding 2.74B
Market Cap 176.50B
EPS 1.40
P/E Ratio 41.10
Div & Yield 1.88 (2.90%)

Latest News

Merck And Premier Inc. Expand Collaboration To Address Chronic Care And Vaccination Rates

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Premier Inc.

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.

Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects

Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects

Paul Clancy's move to another biotech firm could mean that there's nothing imminent in terms of Biogen being bought out, says Mizuho analyst Salim Syed.

Merck Shares Trade Down After 2 Late-Stage Trials Suspended

Merck Shares Trade Down After 2 Late-Stage Trials Suspended

The company is hitting pause on immunotherapy trials for its Keytruda drug to investigate more reports of deaths in trial groups.

Merck Provides Update On Multiple Myeloma Studies KEYNOTE-183 And 185 Of KEYTRUDA® (pembrolizumab) In Combination With Other Therapies

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on two combination studies of KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in the blood cancer multiple...

Merck And Pfizer Announce That Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint In Two Phase 3 Studies

Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc.

Initiating Position in Biotech; Update on ACRX

We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.

Moving on From Merck

We were playing with the house's money on this one.

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

Updated Data From KEYNOTE-024 Show Continued Overall Survival Benefit Of Merck's KEYTRUDA® (pembrolizumab) Compared To Chemotherapy In The First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With High Levels Of PD-L1

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated overall survival (OS) findings from KEYNOTE-024, the phase 3 study evaluating KEYTRUDA ® (pembrolizumab), the company's...

New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes With Combination Of Merck's KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy In Patients With High-Risk Breast Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and QuantumLeap Healthcare Collaborative, today announced results from the Phase 2 I-SPY 2 TRIAL investigating KEYTRUDA ® (pembrolizumab), Merck's...

Updated Data From ECHO-202 Trial Of Incyte's Epacadostat In Combination With Merck's KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity Across Multiple Tumor Types

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte's...

Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study

Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study

Incyte's actions are another reminder that biotech companies carefully groom and manage the clinical data they want investors to see, even at important, open medical meetings like ASCO.

New Monotherapy Data For Merck's KEYTRUDA® (pembrolizumab) In Heavily Pre-Treated Patients With Advanced Gastric Cancer To Be Presented At 2017 ASCO Annual Meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from Cohort 1 of the phase 2 registrational KEYNOTE-059 trial investigating KEYTRUDA ® (pembrolizumab), the company's...

With More Than One-Year Follow-Up, Merck's KEYTRUDA® (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy As Second-Line Treatment For Advanced Urothelial Carcinoma Patients Post-Platinum Failure

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-045 and KEYNOTE-052, two studies investigating KEYTRUDA ® (pembrolizumab), the company's anti-PD-1...

Combination Of Incyte's Epacadostat Plus Merck's KEYTRUDA® (pembrolizumab) Demonstrates Activity In Clinical Trial Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the advanced non-small cell lung cancer (NSCLC) patient cohort of the ongoing Phase...

Incyte 'IDO' Combination Lung Cancer Results Improve Slightly at ASCO17

Incyte 'IDO' Combination Lung Cancer Results Improve Slightly at ASCO17

Incyte and Merck are combining two cancer immunotherapy drugs to treat patients with non-small cell lung cancer.

New Data Show Durability Of Response For Merck's KEYTRUDA® (pembrolizumab) In Advanced Microsatellite Instability-High (MSI-H) Or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless Of Tumor Type

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of findings from KEYNOTE-164 and KEYNOTE-158, two phase 2 studies evaluating KEYTRUDA ® (pembrolizumab), the...

Longer Term Follow-Up Data With Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed And Carboplatin In First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) To Be Presented At 2017 ASCO Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-021, Cohort G1, which studied KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in...

Loxo Drug Notches Strikingly High Response Rates in Genetically Defined Tumors

Loxo Drug Notches Strikingly High Response Rates in Genetically Defined Tumors

The Loxo data also represent another advance for precision cancer medicine, in which patients are treated with drugs that target specific tumor mutations, regardless of where the cancer originates.

With Nearly Three Years Of Follow-Up, KEYTRUDA® (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared To Ipilimumab In Advanced Melanoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated longer-term overall survival (OS) data from KEYNOTE-006, the phase 3 study evaluating KEYTRUDA ® (pembrolizumab), the...

Merck To Present At The Bernstein's 33rd Annual Strategic Decisions Conference

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

Merck Highlights Ongoing Commitment To Fighting Infectious Diseases With More Than 20 Data Presentations At ASM Microbe 2017

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 20 scientific data presentations on the company's established and investigational...

Optum And Merck Collaborate To Advance Value-Based Contracting Of Pharmaceuticals

Optum, the health services business of UnitedHealth Group (NYSE: UNH), and Merck (NYSE: MRK, known as MSD outside the U.

Merck Enters Exclusive Worldwide License Agreement With Teijin Pharma For Investigational Antibody Candidate Targeting Tau

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into an exclusive worldwide license agreement with Teijin Pharma for the development, manufacture and...

I Can't Swallow the 'Plunge Team'

If it limits volatility, how has the market fallen?